Cite
HARVARD Citation
Moebius, H. et al. (n.d.). ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer's disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial. Alzheimer's & dementia. p. n/a. [Online].